September 22, 2022 – The big idea here is that the mRNA revolution that enriched Moderna and BioNTech could benefit a lot from some refinement. If they can keep on failing to fail, Orna has potential to evolve into a leader in the mRNA 2.0 space.
September 22, 2022 – The big idea here is that the mRNA revolution that enriched Moderna and BioNTech could benefit a lot from some refinement. If they can keep on failing to fail, Orna has potential to evolve into a leader in the mRNA 2.0 space.